AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25473190 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg per day for 2 weeks (2W group)
Number of subjects: 60
Study 25473190 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 20 mg per day for 4 weeks (4W group)
Number of subjects: 60
Study 21870906 — intervention group
Group type: EXPERIMENTAL
Intervention: Red clover isoflavones (80 mg, two daily capsules)
Number of subjects: 109
Study 21870906 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equal appearance)
Number of subjects: 109
Study 20367823 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Alliance training (expert group)
Number of subjects: 113
Study 20367823 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Alliance training (novice group)
Number of subjects: 113
Study 20367823 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline comparison)
Number of subjects: 113
Study 20367823 — intervention group
Group type: COMPARATOR
Intervention: Post-test scores comparison
Number of subjects: 113
Study 18374024 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ceftriaxone
Number of subjects: 97
Study 18374024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 15680290 — intervention group
Group type: EXPERIMENTAL
Intervention: eszopiclone 1mg
Number of subjects: 436
Study 15680290 — intervention group
Group type: EXPERIMENTAL
Intervention: eszopiclone 2mg
Number of subjects: 436
Study 15680290 — intervention group
Group type: EXPERIMENTAL
Intervention: eszopiclone 3mg
Number of subjects: 436
Study 15680290 — intervention group
Group type: EXPERIMENTAL
Intervention: eszopiclone 3.5mg
Number of subjects: 436
Study 15680290 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 436
Study 12057880 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained Hispanic lay advocates (Embajadoras)
Number of subjects: 98
Study 12057880 — intervention group
Group type: COMPARATOR
Intervention: Untrained Hispanic women
Number of subjects: 98
Study 12057880 — intervention group
Group type: COMPARATOR
Intervention: Untrained Anglo controls
Number of subjects: 98
Study 10471986 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg daily for 11 days
Number of subjects: 20
Study 10471986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8734139 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg (morning dose), increased to 10 mg if clinically effective
Number of subjects: 83
Study 8734139 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem 180 mg (in three divided doses), increased to 240 mg if clinically effective
Number of subjects: 83
Study 1833969 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser probe (initially used as a nonheated mechanical device, then heated if unsuccessful)
Number of subjects: 20
Study 1833969 — intervention group
Group type: COMPARATOR
Intervention: Standard guidewire and balloon dilation method
Number of subjects: 20
Study 6138935 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (nonselective, 10 mg)
Number of subjects: 8
Study 6138935 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (beta 1‐receptor selective, 100 mg)
Number of subjects: 8
Study 6138935 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (15 mg)
Number of subjects: 8
Study 6138935 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg)
Number of subjects: 8
Study 6138935 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (cardioselective, 500 mg)
Number of subjects: 8
Study 6138935 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-selective blockade (pindolol)
Number of subjects: 8
Study 31901648 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Power intervention (24-session universal prevention adaptation)
Number of subjects: 839
Study 31901648 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 839
Study 30646532 — intervention group
Group type: EXPERIMENTAL
Intervention: WSP-MR (two packs a day for a total of 132 g of WSP)
Number of subjects: 58
Study 30646532 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (non-WSP group)
Number of subjects: 58
Study 29086798 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance feedback
Number of subjects: 26
Study 29086798 — intervention group
Group type: COMPARATOR
Intervention: General feedback
Number of subjects: 26
Study 26815361 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute stress (n=50)
Number of subjects: 100
Study 26815361 — intervention group
Group type: COMPARATOR
Intervention: Control (n=50)
Number of subjects: 100
Study 24506576 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation-aripiprazole group (RA group)
Number of subjects: 43
Study 24506576 — intervention group
Group type: COMPARATOR
Intervention: Control-aripiprazole group (CA group)
Number of subjects: 43
Study 24506576 — intervention group
Group type: COMPARATOR
Intervention: Control-risperidone group (CR group)
Number of subjects: 43
Study 24506576 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation-risperidone group (RR group)
Number of subjects: 43
Study 22486209 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mL of water before blood donation
Number of subjects: 2464
Study 22486209 — intervention group
Group type: COMPARATOR
Intervention: No water before blood donation (control)
Number of subjects: 2464
Study 22486209 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mL of water
Number of subjects: 2464
Study 22486209 — intervention group
Group type: COMPARATOR
Intervention: No water (control)
Number of subjects: 2464
Study 17207124 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (leaflet and assessment)
Number of subjects: 975
Study 17207124 — intervention group
Group type: COMPARATOR
Intervention: Group A (leaflet only)
Number of subjects: 975
Study 16369229 — intervention group
Group type: EXPERIMENTAL
Intervention: EZE/SIMVA (10/20 mg)
Number of subjects: 0
Study 16369229 — intervention group
Group type: EXPERIMENTAL
Intervention: EZE/SIMVA (10/10, 10/20, or 10/40 mg)
Number of subjects: 0
Study 16369229 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (10 mg)
Number of subjects: 0
Study 16369229 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (20 mg)
Number of subjects: 0
Study 12773609 — intervention group
Group type: EXPERIMENTAL
Intervention: Group homes
Number of subjects: 114
Study 12773609 — intervention group
Group type: COMPARATOR
Intervention: Independent apartments
Number of subjects: 114
Study 10488363 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 24 mg intramuscularly in two divided doses 24 hours apart
Number of subjects: 204
Study 10488363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 8604599 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel 2 mg intravaginally
Number of subjects: 110
Study 8604599 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel 0.5 mg intracervically
Number of subjects: 110
Study 8604599 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel 1 mg intravaginally
Number of subjects: 110
Study 1757608 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% halobetasol propionate ointment
Number of subjects: 127
Study 1757608 — intervention group
Group type: COMPARATOR
Intervention: 0.05% clobetasol 17-propionate ointment
Number of subjects: 127
Study 6623020 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated tablet
Number of subjects: 9
Study 6623020 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcrystalline tablet
Number of subjects: 9
Study 6623020 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule containing enterosoluble granules
Number of subjects: 9
Study 29909057 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted cognitive behavioral stress management (C-CBSM) intervention for 10 weeks
Number of subjects: 260
Study 29909057 — intervention group
Group type: COMPARATOR
Intervention: Non-culturally adapted cognitive behavioral stress management (CBSM) intervention for 10 weeks
Number of subjects: 260
Study 26879693 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled noradrenaline infusion to manipulate blood pressure (BP) during surgery
Number of subjects: 105
Study 25365681 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-day hospital-based transitional care program
Number of subjects: 512
Study 23292523 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg salbutamol
Number of subjects: 65
Study 23292523 — intervention group
Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 65
Study 23292523 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 65
Study 21432607 — intervention group
Group type: EXPERIMENTAL
Intervention: Manualized dialectical behavioural therapy (DBT) plus methylphenidate
Number of subjects: 448
Study 21432607 — intervention group
Group type: COMPARATOR
Intervention: Clinical management plus methylphenidate
Number of subjects: 448
Study 21432607 — intervention group
Group type: COMPARATOR
Intervention: Manualized dialectical behavioural therapy (DBT) plus placebo
Number of subjects: 448
Study 21432607 — intervention group
Group type: COMPARATOR
Intervention: Clinical management plus placebo
Number of subjects: 448
Study 19027409 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean exchange list diet with telephone counseling
Number of subjects: 69
Study 19027409 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 69
Study 17113204 — intervention group
Group type: EXPERIMENTAL
Intervention: High-retrieval tasks
Number of subjects: 0
Study 17113204 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-retrieval tasks
Number of subjects: 0
Study 17113204 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes closed condition (Experiment 3)
Number of subjects: 0
Study 17113204 — intervention group
Group type: COMPARATOR
Intervention: No-task waiting period
Number of subjects: 0
Study 12701995 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine reduction by 90% or greater for 30 days
Number of subjects: 88
Study 12701995 — intervention group
Group type: COMPARATOR
Intervention: Usual caffeine consumption
Number of subjects: 88
Study 10998026 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS)
Number of subjects: 19
Study 10998026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8864022 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated CPB circuits (Group HC)
Number of subjects: 16
Study 8864022 — intervention group
Group type: COMPARATOR
Intervention: Noncoated CPB circuits (Group C)
Number of subjects: 16
Study 1497522 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy in one eye for patients with bilateral threshold retinopathy of prematurity
Number of subjects: 4099
Study 1497522 — intervention group
Group type: COMPARATOR
Intervention: No therapeutic ocular procedures (control group)
Number of subjects: 4099
Study 6603567 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical stapling transection of the oesophagus
Number of subjects: 20
Study 6603567 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transhepatic obliteration
Number of subjects: 20
Study 31111436 — intervention group
Group type: EXPERIMENTAL
Intervention: NOF thresholds
Number of subjects: 264
Study 31111436 — intervention group
Group type: EXPERIMENTAL
Intervention: NOGG thresholds
Number of subjects: 264
Study 29659685 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin supplementation
Number of subjects: 0
Study 29659685 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin combined with long-chain omega-3 fatty acids
Number of subjects: 0
Study 26365144 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave treatment (ESWT)
Number of subjects: 201
Study 26365144 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous lavage (UGPL)
Number of subjects: 201
Study 25835231 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C deficiency (biochemical depletion below 11 µmol/L)
Number of subjects: 322
Study 25835231 — intervention group
Group type: COMPARATOR
Intervention: Normal vitamin C levels
Number of subjects: 322
Study 22284636 — intervention group
Group type: EXPERIMENTAL
Intervention: Bard PowerPICC Solo2
Number of subjects: 53
Study 22284636 — intervention group
Group type: COMPARATOR
Intervention: Cook Turbo-Ject
Number of subjects: 53
Study 19652568 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental posterior instrumentation with 2 levels above and 2 levels below the fracture level fixation
Number of subjects: 72
Study 19652568 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental posterior instrumentation with fracture level screw incorporation
Number of subjects: 72
Study 19652568 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-segment posterior instrumentation with 1 level above and 1 level below
Number of subjects: 72
Study 19652568 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-segment posterior instrumentation with fracture level screw incorporation
Number of subjects: 72
Study 17521930 — intervention group
Group type: EXPERIMENTAL
Intervention: Asasantin (Dipyridamole 200mg/Aspirin 25mg) twice daily (group I; n=39)
Number of subjects: 102
Study 17521930 — intervention group
Group type: EXPERIMENTAL
Intervention: Asasantin plus 75 mg Clopidogrel once daily (group II; n=33)
Number of subjects: 102
Study 17521930 — intervention group
Group type: EXPERIMENTAL
Intervention: Asasantin plus Rheomacrodex (Dextran 40) 100g/L iv; 500 ml (group III; n=30)
Number of subjects: 102
Study 17521930 — intervention group
Group type: COMPARATOR
Intervention: Asasantin (group I)
Number of subjects: 102
Study 17521930 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (group II)
Number of subjects: 102
Study 17521930 — intervention group
Group type: COMPARATOR
Intervention: Rheomacrodex (group III)
Number of subjects: 102
Study 17521930 — intervention group
Group type: COMPARATOR
Intervention: All APT groups
Number of subjects: 102
Study 15567642 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-spinal anesthesia
Number of subjects: 150
Study 15567642 — intervention group
Group type: COMPARATOR
Intervention: Propofol-fentanyl anesthesia
Number of subjects: 150
Study 11443224 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg daily for 6 months)
Number of subjects: 106
Study 11443224 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 106
Study 9531962 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen inhalation (very low doses)
Number of subjects: 14
Study 9531962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7974930 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (calcium channel blocker)
Number of subjects: 40
Study 2524959 — intervention group
Group type: COMPARATOR
Intervention: Placebo for both dipyridamole and aspirin
Number of subjects: 12
Study 2524959 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (75 mg) and aspirin (324 mg)
Number of subjects: 12
Study 2524959 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (75 mg) and placebo for aspirin
Number of subjects: 12
Study 4413307 — intervention group
Group type: EXPERIMENTAL
Intervention: Nissen procedure
Number of subjects: 45
Study 4413307 — intervention group
Group type: EXPERIMENTAL
Intervention: Belsey procedure
Number of subjects: 45
Study 4413307 — intervention group
Group type: EXPERIMENTAL
Intervention: Hill procedure
Number of subjects: 45
Study 4413307 — intervention group
Group type: EXPERIMENTAL
Intervention: All procedures
Number of subjects: 45
Study 4413307 — intervention group
Group type: COMPARATOR
Intervention: Nissen and Belsey
Number of subjects: 45
Study 4413307 — intervention group
Group type: EXPERIMENTAL
Intervention: Nissen and Hill repairs
Number of subjects: 45
Study 4413307 — intervention group
Group type: EXPERIMENTAL
Intervention: Belsey repair
Number of subjects: 45
Study 31923231 — intervention group
Group type: COMPARATOR
Intervention: People in prison
Number of subjects: 1530
Study 31923231 — intervention group
Group type: COMPARATOR
Intervention: People recently released from prison
Number of subjects: 1530
Study 30991614 — intervention group
Group type: EXPERIMENTAL
Intervention: Early high-dose erythropoietin (EPO)
Number of subjects: 0
Study 30991614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28249572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem (de-escalation therapy)
Number of subjects: 66
Study 25567131 — intervention group
Group type: EXPERIMENTAL
Intervention: Total arterial grafting (TAG)
Number of subjects: 60
Study 25567131 — intervention group
Group type: COMPARATOR
Intervention: LIMA-LAD plus saphenous vein grafts (LIMA+SVG)
Number of subjects: 60
Study 25567131 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TAG and LIMA+SVG)
Number of subjects: 60
Study 23979082 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic bag intervention
Number of subjects: 271
Study 20978643 — intervention group
Group type: EXPERIMENTAL
Intervention: SolidBond/Durafill (D/SB)
Number of subjects: 42
Study 20978643 — intervention group
Group type: EXPERIMENTAL
Intervention: Syntac classic/Heliomolar (H/SC)
Number of subjects: 42
Study 20978643 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond1/ Experiment127 (EXI/SB1)
Number of subjects: 42
Study 20978643 — intervention group
Group type: EXPERIMENTAL
Intervention: Optibond FL/Point 4 (P4/OBFL)
Number of subjects: 42
Study 20978643 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime&Bond NT/Esthet‐X (EX/PBNT)
Number of subjects: 42
Study 20978643 — intervention group
Group type: EXPERIMENTAL
Intervention: ART Bond/ Miris (MIR/ART)
Number of subjects: 42
Study 20978643 — intervention group
Group type: EXPERIMENTAL
Intervention: SE Bond/Clearfil ST (CLE/SE‐B)
Number of subjects: 42
Study 19860105 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive mechanical ventilation (NIMV)
Number of subjects: 156
Study 19860105 — intervention group
Group type: COMPARATOR
Intervention: Invasive mechanical ventilation (IMV)
Number of subjects: 156
Study 16889454 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg once daily)
Number of subjects: 111
Study 16889454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 15219609 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimuli encoding
Number of subjects: 0
Study 11485511 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined continuous hormone replacement therapy (HRT)
Number of subjects: 61
Study 11485511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 9926277 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine (0.3-0.4 mg/daily)
Number of subjects: 58
Study 7875640 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting conditions (300 mg oral dose of penticainide)
Number of subjects: 16
Study 7875640 — intervention group
Group type: EXPERIMENTAL
Intervention: Fed conditions (300 mg oral dose of penticainide)
Number of subjects: 16
Study 7875640 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting conditions (males)
Number of subjects: 16
Study 7875640 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting conditions (females)
Number of subjects: 16
Study 7875640 — intervention group
Group type: EXPERIMENTAL
Intervention: Fed conditions (males)
Number of subjects: 16
Study 7875640 — intervention group
Group type: EXPERIMENTAL
Intervention: Fed conditions (females)
Number of subjects: 16
Study 2460520 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% alcohol (100 ml intragastric administration)
Number of subjects: 0
Study 2460520 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 0
Study 30987664 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg bolus followed by 2 mg/kg/h continuous infusion, reduced to 1 mg/kg/h in postanesthesia care unit)
Number of subjects: 128
Study 30987664 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 128
Study 28238190 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol 40 mg/day
Number of subjects: 192
Study 28238190 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol 500 mg/day
Number of subjects: 192
Study 28238190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 26581881 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-inspired Artificial Pancreas (BiAP)
Number of subjects: 12
Study 26581881 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-inspired Artificial Pancreas (BiAP) with all meals announced
Number of subjects: 12
Study 26581881 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-inspired Artificial Pancreas (BiAP) with no or partial meal announcement
Number of subjects: 12
Study 26581881 — intervention group
Group type: COMPARATOR
Intervention: Standard insulin pump therapy (open-loop)
Number of subjects: 12
Study 23259919 — intervention group
Group type: EXPERIMENTAL
Intervention: Black currant anthocyanins (BCACs)
Number of subjects: 38
Study 23259919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 23259919 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 38
Study 21450590 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Guide intervention
Number of subjects: 2664
Study 18001688 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion complexity (various complexities of moving stimuli)
Number of subjects: 0
Study 18001688 — intervention group
Group type: COMPARATOR
Intervention: Reference comparison interval (motionless stimuli)
Number of subjects: 0
Study 16282436 — intervention group
Group type: EXPERIMENTAL
Intervention: GLU+FRUC (1.0 g/min of GLU + 0.5 g/min of FRUC)
Number of subjects: 8
Study 16282436 — intervention group
Group type: COMPARATOR
Intervention: GLU (1.5 g/min)
Number of subjects: 8
Study 16282436 — intervention group
Group type: COMPARATOR
Intervention: WAT (water)
Number of subjects: 8
Study 12669874 — intervention group
Group type: EXPERIMENTAL
Intervention: MTAD (mixture of a tetracycline isomer, an acid, and a detergent)
Number of subjects: 48
Study 12669874 — intervention group
Group type: COMPARATOR
Intervention: 5.25% sodium hypochlorite
Number of subjects: 48
Study 12669874 — intervention group
Group type: COMPARATOR
Intervention: 17% EDTA
Number of subjects: 48
Study 12669874 — intervention group
Group type: COMPARATOR
Intervention: Sterile distilled water
Number of subjects: 48